Eli Lilly - Comparative Multiple Analysis

Eli Lilly (Comparative Multiple Analysis)

Home Comparative Index Eli Lilly

►Summary | Profile | News | Chart | SWOT | Cash Flow | Comps | Buffett | WACC

Link to services page

placeholder_large_analysis.png

Improve your investment analysis with by seeing the Eli Lilly's Discounted Cash Flow analysis, Eli Lilly's Warren Buffet analysis, and Eli Lilly's Weighted Average Cost of Capital (WACC) Analysis.

Notes on the Comparative Multiple Analysis of Eli Lilly

WikiWealth compares Eli Lilly's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Eli Lilly's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Eli Lilly.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Eli Lilly's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Eli Lilly's Analysis


How does this work? The Comparative Investment Analysis determines the value of Eli Lilly by comparing Eli Lilly financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Eli Lilly.

See the Eli Lilly cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Eli Lilly.

Also, see the Eli Lilly's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Eli Lilly's valuation conclusion for a quick summary.